Artificial Intelligence in Drug Discovery: A Review of AI Approaches for Target Identification

Faustino D. Reyes

ICT Bahrain Polytechnic,PO Box 33349, Isa Town, Bahrain
Email: faustino.reyes@polytechnic.bh

Abstract

Artificial Intelligence (AI) has become a revolutionary solution in drug discovery and development in aspects including high costs, long times, and high failure rates. This review describes the development and focuses on areas where AI has been used for target identification, lead optimization, design of new drugs from scratch and drug repurposing. Deep learning frameworks such as generative adversarial networks (GANs), variational autoencoders (VAEs), and explainable AI (XAI) approaches have been instrumental and comparative progress in enhancing the efficacy and specificity of drug discovery processes. AI has made advances in clinical trials, trial conduct, and participant selection, as well as enhanced patient-tailored therapies for personalized medicine. Issues such as data credibility, model explainability, and algorithmic biases are still present, and logical and social sciences' cooperation and code of conduct are needed. As such, this review aligns current developments with these challenges to demonstrate the possibilities of AI in revolutionizing pharma research and enhancing health solutions worldwide.

Keywords: Artificial Intelligence; Machine Learning; Drug Discovery; Generative Models; Clinical Trials; Personalized Medicine.

1. Introduction

Artificial Intelligence (AI) and Machine Learning (ML) are emerging innovative tools that can resolve the problems that have long plagued drug discovery. Notably, these technologies are revolutionizing significant steps in the drug discovery process, such as target identification and validation, lead identification and optimization, de novo design and drug repositioning. Sophisticated deep learning techniques, such as GANs and VAEs, are now allowing chemists to design new drugs with desirable pharmacological profiles. AI is also helpful in clinical trials and individualized medicine by selecting the most appropriate methodology for

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

conducting the trials, better-selecting patient populations for clinical trials, and tailoring treatments to particular patients. This review endeavors to discuss the current developments, techniques, and uses of AI in drug discovery, focusing on its impact on redesigning pharmaceutical research and advancing healthcare delivery.

i. AI and ML in Drug Discovery

AI and ML are revolutionizing the first stages of drug discovery through the accurate identification of targets, the selection of leads and drug redeployment. An area known as target identification or target selection is crucial in drug development. Since AI can parse through extensive biological and genomic data sets, it can quickly and accurately identify localized high-yield drug targets. Another example is lead optimization, the process that once had to be carried out through several experimental cycles, which is now boosted with AI algorithms that estimate the molecules' properties and make new improvements to the compound for increased effectiveness or reduced toxicity. The ability of AI to construct entirely novel structures countered in the context of de novo drug design has also displayed the capability of creating novel and potentially useful drug-like material with favorable bioactivity. In addition, other AI applications for drug repurposing, including Deep, reveal drug treatments, hence cutting costs and development time [1], [2].

ii. Automated generative models for drug development

Some of the most conventional generative models can be attributed to GANs and VAEs, and both types have paved the way to de novo drug design. These models create new compounds by training from given molecular data and synthesizing drug-like structures tailored to a particular disease's gene targets. For example, DDR1 kinase inhibitors and CDK20 inhibitors produced with the help of generative frameworks prove that AI can design particular therapeutic agents. The second most important generative method is reinforcement learning, which fine-tunes the lead compounds by refining their structures. This section discusses how these models are revolutionizing drug discovery through the ability to perform fast and exhaustive searches in their space and generate compound candidates with specific pharmacological profiles [3].

iii. Molecular Simulations and Computation Chemistry

This information is supported by molecular simulations that provide relevant 'bottom-up' information about the interactions between drugs and proteins at the molecular level, which AI lacks. Whereas the information management technology of AI uses predictions based on past data, molecular simulations apply physical approaches and laws to predict the binding forces and develop better drugs. These simulations allow the retention of detailed structural and dynamic information on drug candidates, which is essential in optimizing efficacy and reducing side effects. When molecular simulations are combined with AI, then the best features of both techniques can be utilized, resulting in increased efficiency and precision of results. This section focuses on how using AI-based prediction as a top-down process alongside molecular simulations as a bottom-up process shortens the drug discovery process and prevents potential failure in the validation phase [4].

iv. Artificial intelligence in clinical research and biomarker-based medicine

When it comes to clinical trials and the concept of 'precision medicine' per se, AI represents a significant step forward in putting the patient at the center of interventions. In clinical trials, AI can improve trial design, select participants, and dissect large data sets, ultimately increasing efficiency while decreasing price. For instance, AI means that patient cohorts can be screened and partitioned by genetics or other clinical characteristics, guaranteeing that trials are run with better control and give meaningful results. In addition to offsetting the risk and cost of treatment in the clinical trial setting, real-world data and predictive therapeutic

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

responses enhance personalized medicine, another area AI enhances. Real-time drug dosing and drug combination are enhanced through the use of curated AI tools such as CURATE.AI. In contrast, AI models offer synergistic potential through the prediction of beneficial interactions together with the prevention of adverse interactions. These innovations show that AI improves patient conditions and makes healthcare more accurate and efficient [5], [6].

v. Optimization of ethical and technical decisions

However, there are some challenges to using this technology in drug discovery and development in certain aspects. Education factors that affect its credibility include data refinement, algorithm biases, and the absence of interpretability. This is because data is perhaps the most important aspect of anything being predicted and quality; credible data is complex, and erratic data still remains an issue within modern society. In addition, the questions of the objectivity and fairness of the AI algorithms used should be better solved to establish trust between researchers and practitioners. This section focuses on the barriers to AI in drug discovery and calls for multi-disciplinary collaboration between AI specialists and pharmaceutical scientists to construct sound, open and validated AI solutions [7].

AI and ML are an exciting shift in the pharmaceutical industry's approach as they enable quicker, more efficient, and inexpensive creation of new medication. The gamification of medical applications, molecular simulation, and use of AI for clinical trial redesigning have made old concepts bearish and brought together proper patient treatment by prescribing personalized approaches. However, the issues of input data quality, the model's interpretability, and its social impact should not be underestimated when implementing AI capabilities. Integrating multi-disciplinary endeavors accompanied by sustained advancement in strong AI systems, the pharmaceutical sector has the potential to expand the possibilities of new treatments. The progress described in this review points to an era when AI not only streamlines the drug discovery process but also transforms the world's healthcare system, making it possible to deliver the best treatments to the patient in need.

Literature Review

The advancement of artificial intelligence (AI) in drug discovery has shattered the well-known paradigms in the pharma industry, including high costs, long-term success rates, and low success rates. Recent developments in ML and computing technology improve target identification, de novo drug design, and drug delivery systems. Technologies such as generative models and AI predictive tools have helped speed up the process and deliver personalized solutions to treatment plans. These innovations include but are not limited to, cancer treatment and compatibility of traditional medicine, nanomedicine and Poly pharmacology, among others. The present review provides an overview of the current trends, opportunities, and issues of AI in drug discovery, focusing on its extensive application in various fields.

As outlined in [8], molecular property prediction is fundamental in drug discovery, leveraging graph neural networks to utilize molecular graph representations. While these models have succeeded across various applications, their decision-making process often lacks transparency. This work introduces the adaptation of concept whitening to graph neural networks. This explainability method creates inherently interpretable models by identifying concepts and molecular structural components relevant to output predictions. Evaluations on benchmark datasets from MoleculeNet demonstrate that incorporating concept whitening layers enhances classification accuracy and interpretability.

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

As outlined in [9], AlphaFold's ability to predict protein structures for the entire human genome significantly advances artificial intelligence and structural biology. Despite varying confidence levels, these predictions hold promise for structure-based drug design, particularly for targets lacking experimental structural data. By integrating AlphaFold into an AI-powered drug discovery pipeline combining PandaOmics and Chemistry42 platforms, researchers identified a first-in-class small molecule hit for CDK20 with a Kd value of 8.9 ± 1.6 μM, requiring only 30 days and the synthesis of seven compounds. A subsequent iteration yielded a more potent molecule with a Kd value of 210.0 ± 42.4 nM, achieved within the same timeframe and synthesizing six additional compounds, highlighting AlphaFold's transformative potential in early-stage drug discovery.

As detailed in the paper [10], integrating artificial intelligence and machine learning has revolutionized drug discovery, highlighting the importance of transparency and interpretability in these increasingly complex models. Expanded AI (XAI) is arguably the most important methodology since it provides insights into the predictions made by machine learning models. The review considers current practical approaches in XAI. It discusses their use in tasks such as target rebound design and toxicity prediction while addressing the challenges and limitations of these techniques. It also proposes future research directions to enhance the impact of XAI in drug discovery, emphasizing its transformative potential for the field.

As discussed in [11], deep learning in artificial intelligence holds significant potential for advancing drug discovery and chemical biology, particularly in protein structure prediction, molecular bioactivity, organic synthesis planning, and de novo molecule design. While ligand-based approaches have dominated the field, structure-based drug discovery offers a pathway to address unresolved challenges like affinity prediction for novel protein targets and elucidate binding mechanisms. This review highlights key algorithmic concepts in structure-based deep learning and explores the opportunities, applications, and challenges shaping the future of AI-guided drug discovery.

As outlined in [12], modern artificial intelligence, empowered by advancements in computing, large biomedical datasets, and profound learning breakthroughs, offers transformative potential to accelerate drug discovery. The study categorizes AI-driven drug discovery into three sub-areas: representation learning for molecular sequences and geometric graphs, data-driven reasoning for molecular property prediction, compound optimization, de novo molecule generation, synthesis planning, and knowledge-based reasoning utilizing biomedical knowledge graphs. The paper also addresses open challenges and outlines future research directions to expand the impact of AI in drug discovery.

In the research presented in [13], advancements in computational omics technologies have revealed the hidden diversity of natural products, offering new opportunities for drug discovery. The study highlights integrating artificial intelligence, particularly machine learning, to enhance computational drug design through biological activity prediction and de novo drug design. It explores current and potential synergies between these technologies to identify drug candidates efficiently while addressing challenges such as the need for high-quality training datasets and effective algorithm validation strategies.

As discussed in [14], artificial intelligence is emerging as a transformative tool in drug discovery, offering solutions to challenges such as lengthy timelines, high costs, and low success rates. AI algorithms enable rapid identification of drug targets, compound screening, and predictive modeling for efficacy and safety assessments. Notable advancements include the use of AlphaFold2 for protein structure prediction and AI-guided compound design, which have significantly accelerated drug discovery processes. Despite these innovations, AI-designed drugs have yet to achieve clinical approval, underscoring ongoing challenges and the need for robust regulatory guidelines and model trust.

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

As outlined in [15], the potential of artificial intelligence in small-molecule drug discovery is both ambitious and complex, promising rapid identification of hit compounds through virtual screening. However, the field faces significant challenges, including limited transparency from biopharma companies and resource constraints in academia that hinder thorough validation of methodologies. The overwhelming hype surrounding AI often obscures tangible progress, emphasizing the need for more transparent reporting and validation efforts to advance the field.

As detailed in the paper [16], colorectal cancer remains a major cause of cancer-related mortality, with significant variability in treatment outcomes due to its heterogeneous nature. Artificial intelligence has emerged as a powerful tool in personalized medicine, enabling enhanced diagnosis, treatment planning, and outcome prediction in colorectal cancer. AI models can identify biomarkers, predict treatment responses, and guide therapy selection by analyzing genomic, clinical, and imaging data. This approach facilitates targeted therapies, improves survival rates, reduces side effects, and optimizes early detection and disease monitoring, showcasing the transformative potential of AI in advancing colorectal cancer care.

As outlined in [17], artificial intelligence transforms the pharmaceutical industry, particularly in drug discovery and delivery systems. By leveraging advanced machine learning and deep learning techniques, AI enables precision, efficiency, and personalization in drug development. The study highlights AI's ability to process vast datasets, uncover correlations, and provide accurate predictions, revolutionizing various stages from formulation screening to clinical applications. Personalized medicine benefits from AI algorithms that analyze real-world patient data, optimizing treatment outcomes and adherence. Integrating AI into drug delivery research marks a paradigm shift, enhancing the efficiency and precision of pharmaceutical practices.

As discussed in [18], artificial intelligence has introduced transformative tools for exploring the compatibility of Traditional Chinese Medicine (TCM), enabling efficient analysis of its multichemical components. AI technologies such as virtual screening, target prediction, ADMET prediction, and data mining facilitate the study of TCM combinations, mechanisms, and compatibility ratios. These advancements enhance research efficiency while reducing costs. However, the study emphasizes the necessity of traditional expertise to validate AI predictions, highlighting the need for improved tools and interdisciplinary collaboration to advance TCM research further.

As detailed in the paper [19], lung cancer remains a significant global health challenge, with high incidence rates in China. Artificial intelligence is increasingly pivotal in lung cancer drug clinical trials, enhancing preclinical drug discovery, trial design, participant recruitment, and data analysis. AI facilitates the integration and analysis of extensive datasets, identifying novel drug targets and repurposing existing drugs while optimizing trial designs and participant selection. The study underscores the transformative potential of AI in clinical trials and highlights the importance of high-quality data collection and improved interpretability to maximize its benefits.

As outlined in [20], the pharmaceutical industry increasingly leverages computational science approaches, including artificial intelligence and molecular simulations, to enhance drug discovery efficiency. AI-based methods predict potential applications for new drugs by analyzing accumulated knowledge, while molecular simulations provide atomic-level insights into drug-protein interactions using physical laws. These complementary techniques aim to reduce costs and failure rates in drug development. The study emphasizes the future focus on integrating AI and molecular simulations to create novel methodologies that further optimize the drug discovery process.

As detailed in the paper [21], Generative Artificial Intelligence (GenAI) is revolutionizing drug design by accelerating the development process by generating novel molecular structures, lead compound optimization,

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

and de novo drug design. The study explores various generative models, such as variational autoencoders, generative adversarial networks, and reinforcement learning, highlighting their applications in compound generation and molecular representation. GenAI addresses challenges like navigating complex chemical spaces and overcoming data limitations, enhancing efficiency in preclinical screening. Despite its transformative potential, the research emphasizes the need for further optimization and exploration of GenAI models to maximize their impact on drug development.

As outlined in [22], artificial intelligence and machine learning are transforming drug discovery by addressing challenges like high costs, lengthy development times, and frequent failures. Advanced models, including deep neural networks, convolutional neural networks, and generative frameworks like GANs and VAEs, streamline processes such as target identification, lead optimization, de novo drug design, and drug repurposing. Examples include the development of DDR1 kinase inhibitors and CDK20 inhibitors, showcasing AI's ability to create precise therapeutics. AI further supports polypharmacology and combination therapies by predicting multi-target interactions and drug synergies while enhancing nanomedicine through real-time dosing models like CURATE.AI. The study underscores the need for improved data quality, model transparency, and ethical practices to fully realize AI's potential in revolutionizing drug discovery and personalized medicine.

A summary of the paper's literature review is provided in Table 1, emphasizing specific works done on the use of artificial intelligence (AI) in drug discovery and development. Some important contributions of the focus areas of each study are mentioned in the table, including molecular property prediction, protein structure modeling and generative AI techniques. For instance, experiments incorporating graphical neural networks and AlphaFold have enhanced molecular property classification and the speedy procurement of drugs, respectively. Other works focus on using machine learning to identify biomarkers, improve drug solubility and identify design improvements in clinical trials. Together, these studies demonstrate AI's capacity for introducing significant changes to the world of pharmaceutical research and development by enhancing speed and individualization, as well as within the framework of real-life concerns, such as delivering transparent and stable models that can work with unrelated data.

Table 1: Summary of Literature Review

Reference Number	Focus Area	Key Contributions
[8]	Molecular property prediction using graph neural networks	Enhanced classification accuracy and interpretability using concept whitening layers
[9]	AlphaFold in protein structure prediction and drug discovery	Identified CDK20 inhibitors, demonstrating rapid drug discovery capability
[10]	Explainable AI (XAI) for enhanced drug discovery insights	Improved model transparency and interpretability in machine learning applications
[11]	Deep learning for protein structure and ligand interactions	Highlighted structure-based drug discovery for affinity prediction and binding elucidation

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

[12]	AI-driven sub-areas in drug discovery (representation, reasoning, knowledge)	Categorized AI advancements in drug representation, optimization, and reasoning
[13]	Computational omics technologies for natural product drug discovery	Integrated AI for activity prediction and optimization in natural product discovery
[14]	AI in drug target identification and predictive modeling	Highlighted AlphaFold2 for protein prediction and AI-guided compound design
[15]	Challenges in small-molecule drug discovery using AI	Addressed resource constraints and the need for transparency in drug development
[16]	AI in colorectal cancer diagnosis and treatment optimization	Biomarker identification, treatment prediction, and early detection optimization
[17]	AI in drug delivery systems and personalized medicine	Optimized drug formulation, screening, and real-world data analysis
[18]	AI in Traditional Chinese Medicine Compatibility Analysis	Predicted TCM combinations and optimized compatibility ratios
[19]	AI in lung cancer clinical trials and drug development	Streamlined trial designs, participant recruitment, and data analysis in lung cancer
[20]	Integration of AI and molecular simulations in drug discovery	Combined AI top-down prediction with molecular simulation bottom-up analysis
[21]	Generative AI (GenAI) for molecular and drug design	Accelerated de novo drug design using GANs, VAEs, and reinforcement learning
[22]	Comprehensive AI applications in drug discovery processes	Developed innovative drugs like DDR1 kinase inhibitors and enhanced Polypharmacology

Introducing AI in the drug discovery concept has already shown efficiency in making previous processes faster and more personalized regarding patient treatment outcomes. In as many ways, AI-driven technologies are revolutionizing pharmaceutical research, from the efficient generation of compound libraries to the optimization of clinical trials and integration of both traditional and contemporary medicines in the drug discovery process. However, issues like data quality, interpretability of the models on hand, and ethical issues

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

are still areas of concern up to the time large-scale implementation is considered. Solving these problems will be crucial to realizing AI's potential in drug development and therapeutic inventions. AI is the stepping stone that is likely to advance better and more efficient healthcare as the field grows, becoming one of the greatest inventions to change the face of medicine.

2. Discussion

i. Transformative Impact of AI in Drug Discovery

AI is revolutionizing the drug discovery process because it provides solutions such as increased drug discovery costs, labor intensity, and high failure rates. Innovation of state-of-the-art models like graph neural networks, GANs, and VAEs has steered target identification, de novo drug designing and drug repositioning. Because of its ability to evaluate big data and model molecular behavior, AI eliminates numerous experimental loops, making the processes more efficient and accurate. However, there is a significant demand for understanding the details employed when using AI techniques in pharmaceutical research to give proper credit and to have a basis towards which the results can be replicated [23].

ii. Artificial Intelligence in Clinical Trial and Precision Medicine

AI has positively impacted clinical trials through trial design improvement, better participant selection and big data analysis for better insights. Allowing real-time drug dosing, as well as showing possible synergistic or toxic drug combinations, CURATE.AIS promotes better therapeutic results. In personalized medicine, artificial intelligence concepts involve finding biomarkers, selecting patient populations, and delivering treatment programs focusing on the patient. Such innovations help to minimize dangers and expenses and open the means of developing individualized and efficient health management systems [24].

iii. Ethical and Technical Consideration

However, AI has many issues when applied to drug discovery technology. Some of them include lacking data quality, algorithmic bias and lack of capacity for explainability. Lack of standard datasets and inadequate data refining cause variability in results and complex AI models, which might be biased. Solving all these requires interdisciplinary programs that include both AI and other drug discovery and development researchers, as well as enhanced clear, valid, and ethical AI models [25].

iv. Future Lines and Further Research Directions

The use of AI as a core technology in drug discovery means that the future of this area is a combined effort with other technologies like molecular simulations and omics data. Integrating AI's large-scale prediction with a molecule-by-molecule approach used in molecular simulations improves drug discovery pipelines. However, integrating multiple omics data and multimodal artificial neural networks may help enhance our understanding of pathology and drug interactions. Exploration of the XAI methodologies and high-quality datasets will eventually enhance model reliability and actualization in industries such as pharmaceutical [26].

AI can effectively be applied in drug discovery, development, and personalized medicine, making the processes faster and enhancing patient care quality. First, AI has struck gold with target identification and clinical trials, representing notable pain points in earlier paradigms. Still, its potential is not widely realized due to ethical and technical challenges, the need to focus on data quality and project interdisciplinary

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

cooperation. By overcoming such challenges, AI will revolutionize global healthcare by delivering improved, faster, more effective, and accessible treatments.

3. Conclusion

Incorporating Artificial Intelligence (AI) in drug discovery and development has been considered the paradigm shift of drug discovery. AI has dramatically impacted the drug development process by implementing the handling of large data sets, the creation of new molecular structures, and accurate computer modeling of biological interactions at different levels throughout the drug development process of Drug discovery. Discussing the applications across the drug discovery value chain—from identification of the therapeutic target to the de novo design of a drug, molecular modeling, and prediction of its pharmacokinetics and toxicity, to clinical trials and precision medicine, the author reveals how AI has reinvented conventional methods, cutting the time and expenses and enhancing the efficacy of treatments. Such innovations show AI's capability to bring a change in the pace of development and improvement that might transform the healthcare industries worldwide.

However, there are problems with the extensive use of artificial intelligence across the industry. Questions concerning data, its reliability, and clarity of outcomes are still challenges that hinder the AI solution's stability and proliferation. High-quality data is important because low-quality data or inconsistency in data actually leads to lousy prediction or even estimate; secondly, the black box problem associated with most AI algorithms raises several issues about fairness and ethical considerations. Meeting such barriers requires the development of interpretable models and reliable datasets. Speakers also emphasized the need for coordination between AI researchers, pharmacologists and policymakers to guarantee that AI is only used correctly in drug discovery.

The next step should be the research of synergistic use of AI in conjunction with other methodologies like molecular simulation and multi-omics data analysis. Integrating these approaches can improve the ability of AI models to predict the activity of drug-target interaction and disease pathways. Also, the growth of the XAI methodologies will advance increased trust and usage across the industry in the future. This indicates that by integrating other areas of study and enhancing these technologies, AI could be employed to meet the advanced needs of the modern drug discovery process.

With the progression of the pharmaceutical industry, AI remains one of the pinnacles of development that solves inefficiencies, costs, and individual customer care. Addressing existing challenges will lead to the development of consistent and better accessible AI-assisted services that will revolutionize drug development and treatment systems. Therefore, by adopting the essence of AI, the pharmaceutical industry can contribute positively to achieving pressing global health needs by providing the right solutions to deserving society.

References

[1] D. Crucitti *et al.*, “De novo drug design through artificial intelligence: an introduction,” *Frontiers in Hematology*, vol. 3, p. 1305741, Jan. 2024, doi: 10.3389/FRHEM.2024.1305741.

[2] M. Abbasi *et al.*, “Designing optimized drug candidates with Generative Adversarial Network,” *J Cheminform*, vol. 14, no. 1, pp. 1–16, Dec. 2022, doi: 10.1186/S13321-022-00623-6/FIGURES/12.

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

[3] D. R. Serrano *et al.*, "Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine," *Pharmaceutics 2024, Vol. 16, Page 1328*, vol. 16, no. 10, p. 1328, Oct. 2024, doi: 10.3390/PHARMACEUTICS16101328.

[4] D. Crucitti *et al.*, "De novo drug design through artificial intelligence: an introduction," *Frontiers in Hematology*, vol. 3, p. 1305741, Jan. 2024, doi: 10.3389/FRHEM.2024.1305741.

[5] A. Blasiak, J. Khong, and T. Kee, "CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence," *SLAS Technol*, vol. 25, no. 2, pp. 95–105, Apr. 2020, doi: 10.1177/2472630319890316/ASSET/6D78EAD6-3F1A-47B9-B21F-279134B39D68/MAIN.ASSETS/FX1.JPG.

[6] C. Carini, A. A. Seyhan, C. Carini claudiocarini, and click A. Attila Seyhan, "Tribulations and future opportunities for artificial intelligence in precision medicine," *Journal of Translational Medicine 2024 22:1*, vol. 22, no. 1, pp. 1–31, Apr. 2024, doi: 10.1186/S12967-024-05067-0.

[7] C. Carini, A. A. Seyhan, C. Carini claudiocarini, and click A. Attila Seyhan, "Tribulations and future opportunities for artificial intelligence in precision medicine," *Journal of Translational Medicine 2024 22:1*, vol. 22, no. 1, pp. 1–31, Apr. 2024, doi: 10.1186/S12967-024-05067-0.

[8] M. Proietti, A. Ragno, B. La Rosa, R. Ragno, and R. Capobianco, "Explainable AI in drug discovery: self-interpretable graph neural network for molecular property prediction using concept whitening," *Mach Learn*, vol. 113, no. 4, pp. 2013–2044, Apr. 2024, doi: 10.1007/S10994-023-06369-Y/TABLES/13.

[9] F. Ren *et al.*, "AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cyclin-dependent Kinase 20 (CDK20) Small Molecule Inhibitor," Jan. 2022, Accessed: Dec. 18, 2024. [Online]. Available: https://arxiv.org/abs/2201.09647v2

[10] R. Alizadehsani *et al.*, "Explainable Artificial Intelligence for Drug Discovery and Development -- A Comprehensive Survey," *IEEE Access*, vol. 12, pp. 35796–35812, Sep. 2023, doi: 10.1109/ACCESS.2024.3373195.

[11] R. Özçelik, D. van Tilborg, J. Jiménez-Luna, and F. Grisoni, "Structure-based drug discovery with deep learning," *ChemBioChem*, vol. 24, no. 13, Dec. 2022, doi: 10.1002/cbic.202200776.

[12] M. T. Nguyen, T. Nguyen, and T. Tran, "Learning to Discover Medicines," *Int J Data Sci Anal*, vol. 16, no. 3, pp. 301–316, Feb. 2022, doi: 10.1007/s41060-022-00371-8.

[13] M. W. Mullowney *et al.*, "Artificial intelligence for natural product drug discovery," *Nat Rev Drug Discov*, vol. 22, no. 11, pp. 895–916, Sep. 2023, doi: 10.1038/S41573-023-00774-7.

[14] J. Cheng *et al.*, "Accurate proteome-wide missense variant effect prediction with AlphaMissense," *Science (1979)*, vol. 381, no. 6664, Sep. 2023, doi: 10.1126/SCIENCE.ADG7492.

[15] A. Mullard, "When can AI deliver the drug discovery hits?," *Nat Rev Drug Discov*, vol. 23, no. 3, pp. 159–161, Mar. 2024, doi: 10.1038/D41573-024-00036-0.

[16] "(PDF) Innovative Therapeutic Pathways in Colorectal Cancer: An AI- Assisted Personalized Medicine Approach." Accessed: Dec. 19, 2024. [Online]. Available: https://www.researchgate.net/publication/387089287_Innovative_Therapeutic_Pathways_in_Colorectal_Cancer_An_AI-_Assisted_Personalized_Medicine_Approach

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024

[17] S. Gandhi, V. Avhad, K. Raut, N. Javane, and S. Katkhade, "INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND TECHNOLOGY 12 | P a g e Artificial Intelligence in Pharmacy: A Boon for Drug Delivery & Drug Discovery," *Int. J. Sci. R. Tech*, vol. 2024, no. 12, p. 1, Accessed: Dec. 19, 2024. [Online]. Available: www.ijsrtjournal.com

[18] Q. Jiang, S. Yang, S. He, and F. Li, "AI drug discovery tools and analysis technology: New Methods Aids in Studying the Compatibility of Traditional Chinese Medicine," *Pharmacological Research - Modern Chinese Medicine*, p. 100566, Dec. 2024, doi: 10.1016/J.PRMCM.2024.100566.

[19] Y. Zhang *et al.*, "Artificial Intelligence in Clinical Trials of Lung Cancer: Current and Future Prospects," *Intelligent Oncology*, Dec. 2024, doi: 10.1016/J.INTONC.2024.11.003.

[20] H. Iwata, "Transforming drug discovery: the impact of AI and molecular simulation on R&D efficiency," *Bioanalysis*, Dec. 2024, doi: 10.1080/17576180.2024.2437283.

[21] S. Ahmad *et al.*, "Generative AI in Drug Designing: Current State-of-the-Art and Perspectives," pp. 427–463, 2024, doi: 10.1007/978-981-97-8460-8_20.

[22] S. Ambreen, M. Umar, A. Noor, H. Jain, and R. Ali, "Advanced AI and ML frameworks for Transforming Drug Discovery and Optimization: With Innovative insights in Polypharmacology, Drug Repurposing, Combination Therapy and Nanomedicine.," *Eur J Med Chem*, p. 117164, Dec. 2024, doi: 10.1016/J.EJMECH.2024.117164.

[23] D. R. Serrano *et al.*, "Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine," *Pharmaceutics 2024, Vol. 16, Page 1328*, vol. 16, no. 10, p. 1328, Oct. 2024, doi: 10.3390/PHARMACEUTICS16101328.

[24] I. Ghebrehiwet, N. Zaki, R. Damseh, and M. S. Mohamad, "Revolutionizing personalized medicine with generative AI: a systematic review," *Artif Intell Rev*, vol. 57, no. 5, pp. 1–41, May 2024, doi: 10.1007/S10462-024-10768-5/TABLES/6.

[25] R. Alizadehsani *et al.*, "Explainable Artificial Intelligence for Drug Discovery and Development -- A Comprehensive Survey," *IEEE Access*, vol. 12, pp. 35796–35812, Sep. 2023, doi: 10.1109/ACCESS.2024.3373195.

[26] R. Alizadehsani *et al.*, "Explainable Artificial Intelligence for Drug Discovery and Development -- A Comprehensive Survey," *IEEE Access*, vol. 12, pp. 35796–35812, Sep. 2023, doi: 10.1109/ACCESS.2024.3373195.

DOI: https://doi.org/10.54216/MOR.030102
Received: October 23, 2024 Revised: December 06, 2024 Accepted: December 19, 2024